Sandra E. Dunn

7.8k citations
99 papers · 5.3k · h-index 44

Impact in

Papers in

  • Molecular Biology 59
    • RNA Research and Splicing 21
    • Melanoma and MAPK Pathways 10
    • PI3K/AKT/mTOR signaling in cancer 8
  • Oncology 39
    • Cancer Cells and Metastasis 16
    • HER2/EGFR in Cancer Research 12
Co-authors
J. Carl Barrett (5 shared papers)Anna L. Stratford (16 shared papers)Kaiji Hu (18 shared papers)Abbas Fotovati (15 shared papers)Arezoo Astanehe (14 shared papers)Jennifer Law (7 shared papers)Cathy Lee (12 shared papers)Jill E. Kucab (7 shared papers)
Journals
Cancer Research (15 papers)Oncogene (8 papers)Oncotarget (6 papers)Breast Cancer Research (5 papers)Stem Cells (5 papers)
Partner nations
CanadaUnited StatesGermany

In The Last Decade

Sandra E. Dunn

97 papers receiving 5.1k citations

Peers

Sandra E. Dunn
Comparison fields: 5 of 114
  • Cancer Research 954
  • Oncology 1.3k
  • Molecular Biology 3.2k
  • Aging 75
  • Genetics 387
Replace Andrea Morrione with:
Andrea Morrione United States
Silvia Soddu Italy
Antonio Di Cristofano United States
Pradip K. Majumder United States
Masahiro Aoki Japan
Sophie Tartare‐Deckert France
Jianhua Luo United States
Antonino Passaniti United States
Edward A. Fox United States
Jiyong Liang United States
Sandra E. Dunn relative to Andrea Morrione United States Andrea Morrione's profile →
Citations per field
00.5×2×3×3.6×
Andrea Morrione · 1×
Citations per year

Countries citing papers authored by Sandra E. Dunn

Since Specialization
Citations

This map shows the geographic impact of Sandra E. Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra E. Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra E. Dunn more than expected).

Fields of papers citing papers by Sandra E. Dunn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra E. Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra E. Dunn. The network helps show where Sandra E. Dunn may publish in the future.

Co-authors

The 25 scholars most cited alongside Sandra E. Dunn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandra E. Dunn Line = papers co-authored together Sandra E. Dunn links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 99 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice.
PubMed ·Sandra E. Dunn, Frank W. Kari, John E. French, Joel R. Leininger, Greg Travlos, Rebecca L. Wilson, J. Carl Barrett
1997391
2
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
Cancer Research ·Jennifer Law, Golareh Habibi, Kaiji Hu, Hamid Masoudi, Michelle Y.C. Wang, Anna L. Stratford, Eugene Park, Julia M.W. Gee, Pauline Finlay, Helen E. Jones, Robert I. Nicholson, Joan M. Carboni, Marco M. Gottardis, Michaël Pollak, Sandra E. Dunn
2008349
3
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells
Oncogene ·Brent W. Sutherland, Jill E. Kucab, Joyce C. Wu, Cathy Lee, Maggie C.U. Cheang, Erika Yorida, Dmitry Turbin, Shoukat Dedhar, Colleen C. Nelson, Michaël Pollak, H. Leighton Grimes, Kathy D. Miller, Sunil Badve, David G. Huntsman, C Blake-Gilks, Min Chen, Catherine J. Pallen, Sandra E. Dunn
2005251
4
A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer.
PubMed ·Sandra E. Dunn, Melanie Ehrlich, N J Sharp, Krzysztof Reiss, Gili Solomon, R A Hawkins, Renato Baserga, J. Carl Barrett
1998240
5
YB-1: oncoprotein, prognostic marker and therapeutic target?
Biochemical Journal ·Annette Lasham, Cristin G. Print, Adele G. Woolley, Sandra E. Dunn, Antony W. Braithwaite
2012178
6
Molecular Profiling Identifies Prognostic Subgroups of Pediatric Glioblastoma and Shows Increased YB-1 Expression in Tumors
Journal of Clinical Oncology ·Damien Faury, André Nantel, Sandra E. Dunn, Marie-Christine Guiot, Takrima Haque, Péter Hauser, Miklós Garami, László Bognár, Zoltán Hanzély, Paweł P. Liberski, Enrique López‐Aguilar, Elvis Terci Valera, Luíz Gonzaga Tone, Anne‐Sophie Carret, Rolando F. Del Maestro, Martin Gleave, J.L. Martínez Montes, Torsten Pietsch, Stephen Albrecht, Nada Jabado
2007174
7
Hierarchical Clustering Analysis of Tissue Microarray Immunostaining Data Identifies Prognostically Significant Groups of Breast Carcinoma
Clinical Cancer Research ·Nikita Makretsov, David G. Huntsman, Torsten O. Nielsen, Erika Yorida, Michael L. Peacock, Maggie C.U. Cheang, Sandra E. Dunn, Malcolm Hayes, Matt van de Rijn, Chris Bajdik, C. Blake Gilks
2004169
8
Y-Box Binding Protein-1 Induces the Expression of CD44 and CD49f Leading to Enhanced Self-Renewal, Mammosphere Growth, and Drug Resistance
Cancer Research ·Karen To, Abbas Fotovati, Kristen M. Reipas, Jennifer Law, Kaiji Hu, Jing Wang, Arezoo Astanehe, Alastair Davies, Lawrence Lee, Anna L. Stratford, Afshin Raouf, Pauline Johnson, Isabelle M. Berquin, Hans‐Dieter Royer, Connie J. Eaves, Sandra E. Dunn
2010148
9
Identification of ROCK1 kinase as a critical regulator of Beclin1-mediated autophagy during metabolic stress
Nature Communications ·Aditi U. Gurkar, Kiki Chu, Lakshmi Raj, Richard Bouley, Seung‐Hwan Lee, Young‐Bum Kim, Sandra E. Dunn, Anna Mandinova, Sam W. Lee
2013140
10
Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2
Cancer Research ·Joyce C. Wu, Cathy Lee, Daniel Yokom, Helen Jiang, Maggie C.U. Cheang, Erika Yorida, Dmitry Turbin, Isabelle M. Berquin, Peter R. Mertens, Thomas Iftner, C. Blake Gilks, Sandra E. Dunn
2006139
11
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells
Breast Cancer Research ·Anna L. Stratford, Christopher J. Fry, Curtis Desilets, Alastair Davies, (unknown), Yvonne Li, Zigang Dong, Isabelle M. Berquin, Philippe P. Roux, Sandra E. Dunn
2008127
12
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy
Breast Cancer Research ·Anna L. Stratford, Golareh Habibi, Arezoo Astanehe, Helen Jiang, Kaiji Hu, Eugene Park, Ashleen Shadeo, Timon P.H. Buys, Wan L. Lam, Trevor J. Pugh, Marco A. Marra, Torsten O. Nielsen, U. Klinge, Peter R. Mertens, Samuel Aparício, Sandra E. Dunn
2007123
13
Disulfiram, a drug widely used to control alcoholism, suppresses self-renewal of glioblastoma and overrides resistance to temozolomide
Oncotarget ·Joanna Triscott, Cathy Lee, Kaiji Hu, Abbas Fotovati, Rachel Berns, Mary Rose Pambid, Margaret Luk, Richard E. Kast, Esther Kong, Eric Toyota, Stephen Yip, Brian Toyota, Sandra E. Dunn
2012116
14
Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival
Cancer Research ·Armelle A. Troussard, Paul C. McDonald, Elizabeth D. Wederell, Nasrin M. Mawji, Nolan R. Filipenko, Karen A. Gelmon, Jill E. Kucab, Sandra E. Dunn, Joanne T. Emerman, Marcel B. Bally, Shoukat Dedhar
2006106
15
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes
Breast Cancer Research ·Golareh Habibi, Samuel Leung, Jennifer Law, Karen A. Gelmon, Hamid Masoudi, Dmitry Turbin, Michaël Pollak, Torsten O. Nielsen, David G. Huntsman, Sandra E. Dunn
2008103
16
Targeting YB-1 in HER-2 Overexpressing Breast Cancer Cells Induces Apoptosis via the mTOR/STAT3 Pathway and Suppresses Tumor Growth in Mice
Cancer Research ·Cathy Lee, Jaspreet Dhillon, Michelle Y.C. Wang, Yuanyuan Gao, Kaiji Hu, Eugene Park, Arezoo Astanehe, Mien‐Chie Hung, Peter Eirew, Connie J. Eaves, Sandra E. Dunn
200899
17
Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells
Oncogene ·Melanie Finkbeiner, Arezoo Astanehe, Karen To, Abbas Fotovati, Alastair Davies, Yun Zhao, Helen Jiang, Anna L. Stratford, Ashleen Shadeo, Carla Boccaccio, Paolo M. Comoglio, Peter R. Mertens, Peter Eirew, Afshin Raouf, Connie J. Eaves, Sandra E. Dunn
200981
18
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
Breast Cancer Research ·Jill E. Kucab, Cathy Lee, Ching‐Shih Chen, Jiuxiang Zhu, C. Blake Gilks, Maggie C.U. Cheang, David G. Huntsman, Erika Yorida, Joanne T. Emerman, Michaël Pollak, Sandra E. Dunn
200580
19
Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells
Breast Cancer Research ·Kaiji Hu, Jennifer Law, Abbas Fotovati, Sandra E. Dunn
201274
20
Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase.
PubMed ·Sandra E. Dunn, J.V. Torres, J S Oh, David M. Cykert, J. Carl Barrett
200174

About Sandra E. Dunn

Sandra E. Dunn is a scholar working on Molecular Biology, Oncology, Genetics, Cancer Research and Endocrinology, Diabetes and Metabolism, having authored 99 papers that have together received 5.3k indexed citations. Recurring topics across this work include RNA Research and Splicing (21 papers), Cancer Cells and Metastasis (16 papers), Glioma Diagnosis and Treatment (15 papers), HER2/EGFR in Cancer Research (12 papers), Melanoma and MAPK Pathways (10 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Growth Hormone and Insulin-like Growth Factors (7 papers) and Microtubule and mitosis dynamics (6 papers). The work is most often cited by research in Cancer Research (954 citations), Oncology (1.3k citations), Molecular Biology (3.2k citations), Aging (75 citations) and Genetics (387 citations). Sandra E. Dunn has collaborated with scholars based in Canada, United States and Germany. Frequent co-authors include J. Carl Barrett, Anna L. Stratford, Kaiji Hu, Abbas Fotovati, Arezoo Astanehe, Jennifer Law, Cathy Lee, Jill E. Kucab, Michaël Pollak and Frank W. Kari. Their work appears in journals such as Cancer Research, Oncogene, Oncotarget, Breast Cancer Research and Stem Cells.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea MorrioneBreakdown of academic impact, for papers by Silvia SodduBreakdown of academic impact, for papers by Antonio Di CristofanoBreakdown of academic impact, for papers by Pradip K. MajumderBreakdown of academic impact, for papers by Masahiro AokiBreakdown of academic impact, for papers by Sophie Tartare‐DeckertBreakdown of academic impact, for papers by Jianhua LuoBreakdown of academic impact, for papers by Antonino PassanitiBreakdown of academic impact, for papers by Edward A. FoxBreakdown of academic impact, for papers by Jiyong Liang